Form D · Biotechnology

Viewpoint Molecular Targeting, Inc.

Coralville, IA · CIK 0001768245

Offering snapshot reported Jan 15, 2021 · SEC filing

Reported sold
$14.3M
Offering amount: $15.8M
Investors reported
29
Form D · investor count
Minimum accepted
$25K
Reported outside-investor minimum
First sale
Nov 20, 2020
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$7.13M$14.3MDec 4, 2020: $8,843,739.00Dec 4, 2020Dec 30, 2020: $12,038,744.00Dec 30, 2020Jan 15, 2021: $14,258,742.00Jan 15, 2021

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$12,038,744 → $14,258,742
  • Reported investors28 → 29

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 15, 2021Amendment$14,258,742$2,219,998vs Dec 30, 202029SEC filing
Dec 30, 2020Amendment$12,038,744$3,195,005vs Dec 4, 202028SEC filing
Dec 4, 2020Initial$8,843,739No comparison26SEC filing
Jun 18, 2020Amendment$750,000$150,000vs Feb 19, 201910SEC filing
Feb 19, 2019Initial$600,000No comparison7SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$1.01M
Finders' fees
$0
Form D file number
021-382294
Total offering amount is subject to increase by the issuer. Total offering amount and total amount sold include conversion of outstanding debt in the aggregate amount of $847,498.
Cash sales compensation of $956,930.92 and reimbursed expenses of $50,000. Additionally, warrants to purchase 1,070,443 shares of common stock of the issuer at the per share offering price were issued to the broker and its designees.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
National Securities Corporation7569

Source: Form D, filed Jan 15, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Heyward Coleman Director, Executive
Cameron Gray Director
Frances Johnson Director, Executive
Curtis Nelson Director
Michael Schultz Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
2500 Crosspark Road E 116
Coralville, IA, 52241